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disease characteristics at diagnosis were as follows (no. of patients):
male (22), female (11), median age 56 years (range 39–70), Stage II
(9), Stage III (24), IgG (22), IgA (9), free light chain (2). Median
paraprotein at initiation of consolidation was 0 (range 0–3.6) (n 
33), day 1 cycle 4 was 0.1 (range 0–2.1) (n  23), and at end of
study was 0.35 (range 0–3.4) (n  20). With a median follow up of
14 months, disease progression has occurred in 5 patients with 1
death. Fourteen patients (42%) experienced reactivation of VZV, 2
patients had human herpes virus 6 reactivation, and 1 patient had
oral herpes simplex virus reactivation, all requiring therapy. The
median absolute lymphocyte count at the onset of viral reactivation
was 1336/mcl (range  600–4800/mcl). A signiﬁcant difference
was seen in the mean CD8 count just prior to transplantation
between those patients with viral reactivation (243, range 77–685)
and the rest of the study population (392, range 87–1339) (P 
.03). The median time from enrollment to VZV reactivation was
189 days (range 25–375). Ten patients had grade 1/2 and none had
grade 3/4 neuropathy at study enrollment. At initiation of post
transplant bortezomib 21 (64%) had grade 1/2 neuropathy and 1
(3%) had grade 3/4 neuropathy. Treatment emergent neuropathy
on once weekly bortezomib was seen in only 3 patients (9%),
necessitating dose reduction (1 patient) or discontinuation of ther-
apy (2 patients). No grade 3/4 thrombocytopenia or neutropenia
was observed with consolidation bortezomib. We conclude that
bortezomib when administered pre- and post HDCT in MM
patients results in a very high rate of viral reactivation. This ﬁnding
may be explained by a decrease in circulating CD8 T cells and has
implications for future clinical trials of bortezomib in this setting.
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SALVAGE NON-MYELOABLATIVE ALLOGENEIC TRANSPLANTATION AF-
TER FAILURE OF AN AUTOLOGOUS TRANSPLANTATION IN MULTIPLE
MYELOMA
Qazilbash, M.H.1, Saliba, R.1, Mendoza, F.1, Roden, L.1, Hosing, C.1,
Couriel, D.E.1, Kebriaei, P.1, Popat, U.1, De Lima, M.1,
Champlin, R.E.1, Giralt, S.A.1 University of Texas-M. D. Anderson
Cancer Center, Houston, TX.
Introduction: Salvage therapy for patients relapsing after an
autologous stem cell transplant for multiple myeloma is not well
deﬁned. Allogeneic stem cell transplantation with a reduced-
intensity preparative regimen has been one of the approaches
used in this setting. We analyzed the outcomes of 30 patients
who underwent a reduced-intensity allogeneic transplant after
disease progression from the ﬁrst autologous transplant. Meth-
ods: Median age was 51 years (range 32–65). Twenty-two
patients underwent transplants from a related donor (21 HLA-
identical, 1 with a single class 1 antigen mismatch), while 8 from
an unrelated donor (7 HLA-identical, one with a single DQ
mismatch). Preparative regimen in 28/30 patients was a combi-
nation of ﬂudarabine 30 mg/m2  4 days and melphalan 70
mg/m2 IV  2 days (24 patients), while 2 patients received
ﬂudarabine 25 mg/m2 IV  5d and cyclophosphamide 1g/m2
IV  3d. Patients undergoing unrelated donor transplants also
received the rabbit ATG. Tacrolimus and methotrexate were
used for GVHD prophylaxis. The median interval between the
ﬁrst and the second transplant was 18 months. Seventeen pa-
tients had resistant and progressive disease. These patients had
received a median of 5 chemotherapy regimens prior to trans-
plant. In 21/30 patients with available cytogenetic studies, 14
were normal and 7 abnormal. Results: Twenty-one of the 30
patients (70%) achieved a complete (8) or partial response (13).
With a median follow up of 19 months (4–75), 1-year progres-
sion-free survival (PFS) was 24% and 1-year overall survival
(OS) was 59%. Median PFS and OS were 7 and 16 months,
respectively. One-year non-relapse mortality was 17%. Acute
grade II/IV GVHD was seen in 9/30 (30%) and chronic GVHD
in 13/30 (43%: limited 16%, extensive 27%) patients. Disease
progression remained the major cause of failure with 14 (46%)
dying of progressive disease. On univariate analysis, an interval
of 1 year between two transplants was a predictor of early
progression (P  .02) and the presence of progressive/ resistant
disease showed a trend towards shorter overall survival (P 
.07). Conclusions: Salvage allogeneic transplantation can
achieve responses in 70% of heavily pretreated patients, with
acceptable toxicity and durable remissions in patients treated
more than a year after a prior autograft. Patients with chemo-
sensitive disease seem to have a longer overall survival.
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SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE
THERAPY IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IM-
PROVED OUTCOMES IN PATIENTS WITH LONGER DISEASE FREE IN-
TERVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION
Mikhael, J.1, Samiee, S.1, Stewart, A.K.2, Chen, C.1, Trudel, S.1,
Franke, N.1, Winter, A.1, Phillips, D.1, Reece, D.1 1. Princess Margaret
Hospital, Toronto, ON, Canada; 2. Mayo Clinic, Scottsdale, AZ.
Background: Single autologous stem cell transplant (ASCT) is
considered the standard of care for younger multiple myeloma
(MM) patients (pts). However, it is not curative and virtually all
patients will ultimately relapse. The role of a second ASCT as
salvage therapy is unclear. Methods: Retrospective review of all
MM pts who received a second ASCT as salvage therapy at Prin-
cess Margaret Hospital. Results: Between March 1992 and Sep-
tember 2005, 40 MM pts received a second ASCT for relapsed
MM at our institution. Median age was 58 years (range 39–69) at
second transplant. Twenty-one pts were male. Immunoglobulin
subtype included IgG (25), IgA (9), light chain (3), nonsecretory
(2), and IgM(1). Median initial albumin was 42g/l (27–49). In 20
patients in whom cytogenetic studies were available, 3 were posi-
tive for the 13q deletion. Transplant conditioning regimen for ﬁrst
transplant was melphalan (MEL)  TBI  etoposide (E) in 6,
MEL alone in 27, and other regimens in 7 pts. Second ASCT
conditioning consisted of MEL  TBI  E in 2, MEL alone in 37
and BU  CY in 1. Median CD34 counts were 10.96  106/L and
4.85  106/L for ﬁrst and second ASCT, respectively. The median
time from diagnosis to ﬁrst transplant was 9 months (2–74). The
median time to relapse after the ﬁrst transplant was 29 months
(6–85), with a median interval between transplants of 39 months
(6–99). The median time to progression after the second transplant
was 14 months (5–56). One transplant-related death occurred. At
median follow-up after second ASCT of 19 months (1–74), 29
(73%) pts are alive. Nineteen (48% of all pts) are free of disease
progression. The median progression-free survival (PFS) was 18
months and median overall survival (OS) was 41 months after
second ASCT. Long term progression-free status based on the
progression-free interval after ﬁrst transplant is summarized in
(Table1). Conclusions: (1) Second ASCT is a feasible and safe
salvage therapy in relapsed MM patients; (2) second ASCT is
effective in providing median progression-free survival of 18
months and median overall survival of 41 months after second
ASCT; (3) the longer the disease free interval after ﬁrst ASCT the
more effective second ASCT is at extending both progression-free
survival and overall survival.
Table 1. Survival Based on Time to Relapse After 1st ASCT
Interval from
1st ASCT to
Relapse
Number of
Patients
Median Progression
Free Survival after
2nd ASCT
2 Year Overall
Survival After
2nd ASCT
< 24 months 13 17 months 32%
24–36
months 13 29 months 60%
> 36 months 14 54 months 88%
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MCVAC REGIMEN IN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION FOR HIGH-RISK DIFFUSE LARGE B CELL LYM-
PHOMA (DLBCL)
Kato, J.1, Yokoyama, K.1, Mori, T.1, Tsukada, Y.1, Chen, C.-K.1,
Ikeda, Y.1, Okamoto, S.-I.1 Division of Hematology, Department of
Medicine, Keio University School of Medicine, Tokyo, Japan.
Background: High dose chemotherapy followed by autolo-
gous stem cell transplantation in high-risk or relapsed aggres-
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sive non-Hodgkin’s lymphoma (NHL) has been reported to
improve survival. However, optimal conditioning regimen has
yet to be determined. We have conducted a single institute
study to evaluate the safety and efﬁcacy of MCVAC regimen
followed by autologous PBSCT for high-risk NHL. Patients
and Methods: Adult patients with high-risk or relapsed DL-
BCL were eligible. MCVAC regimen consisted of ranimustine
(250 mg/m2 on day 9 and 200 mg/m2 on day 4), cytarabine
(2.0 g/m2 twice daily on days 8 to 5), etoposide (200 mg/m2
twice daily on days 8 to 5), and cyclophosphamide (50 mg/kg
on days 3 and 2) followed by unpurged PBSCT. Granulo-
cyte-colony stimulating factor were intravenously given from
day 1 until neutrophil recovery. Results: Forty patients were
enrolled and evaluable (median age; 51 years old). Disease status
at transplant was CR in 22, and non-CR in 18 patients. Median
follow-up was 33.3 months. Five-year overall survival (OS) and
progression free survival (PFS) were 61.3% and 60.9%, respec-
tively. Five-year OS was 58.1% in CR patients and 63.6% in
non-CR patients (not signiﬁcant), and 5-year PFS was 61.4% in
CR patients and 59.6% in non-CR patients (not signiﬁcant).
Within 30 days after transplant, only 1 patient (2.5%) died of
treatment-related complication (acute myocardial toxicity due
to cyclophosphamide). In 2 patients, secondary MDS/AML was
diagnosed at 20.3 and 94.7 months after transplant. Conclu-
sions: We conclude that MCVAC regimen would be an effec-
tive and tolerable non-TBI regimen in autologous PBSCT for
high-risk or relapsed DLBCL, and disease status at transplant
did not affect the survival.
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ISOPHOSPHORAMIDE MUSTARD-LYSINE (ZIO-201): A POTENTIAL
NEW ALKYLATOR FOR BONE MARROW TRANSPLANTS
Taub, M.1, Springate, J.E.1, Zaki, E.1, Stuck, R.2, Gale, R.P.3 1. State
University of New York, Buffalo, NY; 2. Cancer Medica, LLC, Bir-
mingham, AL; 3. ZIOPHARM Oncology, Charlestown, MA.
Cyclophosphamide (CPA) and ifosfamide (IFOS) are widely
used anti-cancer drugs. High-dose CPA has a special role in
bone marrow transplants but its use is associated with substan-
tial toxicities (kidney, bladder, and CNS) that mandate special
interventions like use of Na-2-mercaptoethane sulfonate
(mesna) and IV hydration. CPA and IFOS are pro-drugs which
must be metabolized before they cross-link DNA via phosphor-
amide (PM) and isophosphoramide mustards (IPM). Adverse
effects of CPA and IFOS result from the metabolites acrolein
(ACR) and chloroacetaldehyde (CCA), which is not directly
involved in DNA-cross-linking. Recently, a lysine-stabilized
form of IPM (IPM-lysine; ZIO-201) was developed. ZIO-201
directly cross-links DNA and is active against human cancer cell
lines and in mice with human cancer xenografts. To evaluate
kidney toxicity of ZIO-201, we used an in vitro primary rabbit
kidney proximal tubule (RPT) cell culture system, which retains
many of the characteristics of renal proximal tubule cells includ-
ing a polarized morphology, a Na/glucose co-transport system
and a p-aminohippurate transport system, glutathione state, and
hormone responses. We studied effects of ZIO-201, ACR, and
CAA on conﬂuent monolayers of primary rabbit kidney proxi-
mal tubule (RPT) cells at 15–100 M. Viability was determined
by neutral red dye uptake. ZIO-201 did not signiﬁcantly reduce
viability; LD50 for CAA was about 40 M with complete inhi-
bition at 75 M. These data show that ZIO-201 avoids the
kidney toxicity caused by metabolites of pro-drugs like CPA and
IFOS. Also, because there is also no inter-subject variability in
metabolism of ZIO-201 (unlike CPA and IFOS) and because
CPA/IFOS-resistant cells are sensitive to ZIO-201, ZIO-201
may be a useful substitute for CPA and/or IFOS in bone marrow
transplant conditioning regimens.
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INTRAVENOUS (i.v.) BUSULFAN (Bu) PLUS MELPHALAN (Mel) IS A
WELL-TOLERATED PREPARATIVE REGIMEN FOR STEM CELL TRANS-
PLANTATION (SCT) IN PATIENTS (pts) WITH ADVANCED LYMPHOID
MALIGNANCIES
Kebriaei, P.1, Madden, T.L.1, Thapar, N.1, Shpall, E.J.1, Hosing, C.1,
Qazilbash, M.H.1, de Lima, M.1, Thall, P.F.1, Wright, S.1,
Khouri, I.F.1, Champlin, R.E.1, Jones, R.1, Andersson, B.S.1 The Uni-
versity of Texas M. D. Anderson Cancer Center, Houston, TX.
High dose chemotherapy and SCT is an accepted treatment option
for pts with relapsed lymphoid malignancies. However, relapse re-
mains a signiﬁcant issue for pts with advanced disease. A double
alkylating regimen of Bu and Mel has been suggested as an effective
and myeloablative pre-transplant conditioning regimen. Historically,
oral Bu was used and the combination resulted in considerable mu-
cositis and VOD. Recently, an i.v. formulation of Bu has been devel-
oped that has less pharmacokinetic variability. We are investigating
the safety and efﬁcacy of i.v. Bu-Mel in pts with lymphoid malignan-
cies undergoing auto- or allo-SCT. Patients and Methods: The
conditioning regimen consists of i.v. Bu 130 mg/m2 over 3 hours daily
for 4 days, either as a ﬁxed dose per BSA, or to target an average daily
AUC of 5000 mMol-min 12% determined by a test dose of i.v. Bu
at 32 mg/m2 given 48 hours prior to the high dose regimen. After the
4 daily Bu doses, there is a rest day, followed by 2 daily doses of Mel
at 70 mg/m2. Stem cells are infused the following day. Dilantin is
administered for seizure prophylaxis. GVHD prophylaxis consists of
tacrolimus and methotrexate for pts receiving allo-SCT. Results:
Twenty-ﬁve pts (17 M/8 F) with median age 40 years (range 19–65):
MM (n  5), NHL (n  5), HD (n  13), ALL (n  2). Median
number of prior chemotherapy regimens was 3 (range 1–8). At study
entry, 2 pts were in CR1; 23 were in relapse: refractory (n  3),
chemo-sensitive ﬁrst relapse (n 9), and beyond ﬁrst relapse (n 11).
Engraftment, GVHD, and toxicity data are shown in Table 1. Grades
I or II mucositis was the most common regimen-related toxicity. Of
note, there were no cases of VOD; reversible hyperbilirubinemia,
grade II (n 2) and grade III (n 1), was observed in 3 pts receiving
allo-SCT. All allo-SCT pts had 100% donor chimerism by day 30.
Twenty pts had i.v. Bu delivered per test dose guidance; 5 pts received
ﬁxed dose Bu at 130 mg/m2. The median daily systemic Bu exposure
was 4867 Mol-min. Conclusions: Intravenous Bu-Mel is well tol-
erated and enables prompt neutrophil and platelet engraftment. In-
dividualized PK-directed dosing of i.v. Bu is feasible, and likely con-
tributes to the low toxicity proﬁle of this regimen. Longer follow-up
is needed to assess disease control (Table 1).
Table 1. Engraftment, GVHD, and Regimen Toxicities
Auto-SCT Allo-SCT
No. Patients 18 7
Median CD34 cell
dose  106/kg
(range)
5.20 (2.49–10.48) 4.89 (2.27–13.31)
Median days to ANC
>0.5  109/L (range)
10 (9–11) 11 (9–19)
Median days to platelet
>20  109/L (range)
9 (8–30) 12 (10–19)
No. patients with
grade II–IV acute
GVHD
0 2
No. patients with
grade III toxicity
2 2
Type grade III toxicity mucositis renal failure,
hyperbilirubinemia
No. Patients with
grade IV toxicity
0 0
No. Deaths with 8
month follow-up
0 2
Cause of death disease progression,
GVHD
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